Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the...| Lupus News Today
Lupus Therapeutics is teaming up with Artiva Biotherapeutics on a Phase 1 trial of AlloNK, a natural killer cell therapy for lupus nephritis.| Lupus News Today